Presentation of discovery data from the GRP78 inhibitor program at EFMC-ISMC 2016

Stockholm, 25 August 2016. Nuevolution AB (publ) (NUE.ST) will present discovery data from the GRP78 inhibitor program at EFMC-ISMC 2016 (EFMC International Symposium on Medicinal Chemistry) in Manchester, UK, on Tuesday 30 August.

The poster presented by Nuevolution scientists is titled “Novel inhibitors of GRP78: Screening a challenging target using the Chemetics® screening platform”. The poster will be available for attendants of the symposium on Monday 29 August and is to be made available on www.nuevolution.com on 29 August at 8:30 CEST.

The GRP78 inhibitor program is in hit-to-lead optimization. The program is developed in collaboration with UK based Cancer Research Technology Discovery Laboratories (CRT-DL) and the Institute of Cancer Research.

In Nuevolution’s Q3 2015/16 report, the company reported that potent small molecules capable of inhibiting GRP78 had been identified, and that three-dimensional crystal structures of these small molecules bound to GRP78 had been obtained. The current compounds are selective and show good potencies for binding of the target in an allosteric manner. The data presented at EFMC-ISMC 2016 are in accordance with this.

For more information, please contact:

Thomas Franch, CSO

Phone: +45 7020 0987

Email: tf@nuevolution.com

Henrik D. Simonsen, CFO

Phone: +45 3913 0947

Email: hs@nuevolution.com


About GRP78

Glucose-regulated protein 78 (GRP78) is a key biological component required for the correct folding and formation of functional proteins inside cancer cells. GRP78 is overexpressed in e.g. certain glioblastomas (brain cancer), prostate cancer and is believed to be relevant for more than 70% of breast cancers. Although more than 4,000 scientific papers have been published on GRP78, no small molecules effectively targeting GRP78 have been reported.

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

Nuevolution AB (publ) is required to disclose the information provided herein pursuant to the Securities Markets Act. The information was sent for publication on Thursday 25 August 2016, 13:00 (CEST).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com

About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas

Subscribe

Documents & Links